Bulletin du Cancer
MENUEpidermal growth factor receptor (EGF) in head-and-neck cancers Volume 94, supplement 6, Suppl. FMC numéro 7 : Thérapeutiques ciblées : malades sélectionnés
Authors
Institut Gustave Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif.
- Key words: EGFR, targeted therapy, association with radiotherapy and chemotherapy
- DOI : 10.1684/bdc.2007.0437
- Page(s) : 189-91
- Published in: 2007
EGFR is frequently overexpressed and is associated with a poor prognosis in head and neck carcinoma (HNC). Among the biological and cellular effects resulting from EGFR targeting, there are the possibilities to restore apoptotic capacities and to reduce DNA-repair activity, to inhibit angiogenesis and tumor cell migration. This suggests the potential interest of the combination between anti-EGFR drugs and cytotoxic agents, especially ionizing radiation with promising results obtained at the clinical level in locally advanced HNC.